Lantheus Holdings Dirección

Dirección controles de criterios 4/4

El CEO de Lantheus Holdings' es Brian Markison, nombrado en Mar 2024, tiene una permanencia de menos de un año. posee directamente un 0.025% de las acciones de la empresa, con un valor de $1.10M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 6.2 años, respectivamente.

Información clave

Brian Markison

Chief Executive Officer (CEO)

US$539.1k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.02%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

May 10

Lantheus Holdings: Powerful First Quarter

May 05

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

Apr 12

Lantheus Holdings: Undervalued With A Good Outlook

Feb 28

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Feb 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

May 29

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Apr 16

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Feb 27

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Jan 16

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Dec 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Oct 31

Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?

Oct 04

Looking In On Lantheus Holdings

Sep 14

Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent

Aug 25

Lantheus Non-GAAP EPS of $0.89 beats by $0.19, revenue of $223.72M beats by $19.21M

Aug 04

Lantheus Holdings (NASDAQ:LNTH) May Have Issues Allocating Its Capital

Jul 22

Lantheus Holdings Rules The Medical Diagnostics Business World

Jul 06

We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease

Jun 25

CEO

Brian Markison (64 yo)

less than a year

Permanencia

US$539,112

Compensación

Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian Markison	CEO & Director	less than a year	US$539.11k	0.025% $ 1.4m
Paul Blanchfield	President	1.2yrs	US$5.31m	0.15% $ 8.2m
Robert Marshall	CFO & Treasurer	5.7yrs	US$4.33m	0.16% $ 9.1m
Daniel Niedzwiecki	Chief Administrative Officer	3.3yrs	US$3.12m	0.14% $ 7.5m
Jean-Claude Provost	Chief Medical Officer	2.1yrs	US$3.08m	0.0083% $ 457.2k
Andrea Sabens	Chief Accounting Officer	2.8yrs	sin datos	0.091% $ 5.0m
Dorothy Barr	Senior Vice President of Manufacturing & Technical Operations	1.9yrs	sin datos	sin datos
Mark Kinarney	Senior Director of Investor Relations	no data	sin datos	sin datos
Linda Lennox	VP of Corporate Communications & Chief of Staff	3.8yrs	sin datos	sin datos
Carol Walker	Senior Vice President of Quality	6.1yrs	sin datos	sin datos
Etienne Montagut	Chief Business Officer	3.3yrs	US$2.51m	0.14% $ 7.5m
Amanda Morgan	Chief Commercial Officer	1.5yrs	sin datos	0.037% $ 2.0m

2.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LNTH se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian Markison	CEO & Director	11.7yrs	US$539.11k	0.025% $ 1.4m
Samuel Leno	Independent Director	12yrs	US$493.31k	0.087% $ 4.8m
James Thrall	Independent Director	6.3yrs	US$483.39k	0.044% $ 2.4m
Mary Heino	Chairman of the Board	8.8yrs	US$12.58m	0.91% $ 50.5m
Minnie Baylor-Henry	Independent Director	2.2yrs	US$477.89k	0.0043% $ 240.2k
Gérard Ber	Independent Director	3.9yrs	US$470.81k	0.049% $ 2.7m
Julie McHugh	Lead Independent Director	7.3yrs	US$479.11k	0.038% $ 2.1m
Gary John Pruden	Independent Director	6.3yrs	US$493.31k	0.045% $ 2.5m
Heinz Mausli	Independent Director	3.9yrs	US$480.00k	0.036% $ 2.0m

6.3yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de LNTH se considera experimentada (6.2 años de antigüedad promedio).

Lantheus Holdings Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

CFO & Treasurer notifies of intention to sell stock

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Chairman of the Board notifies of intention to sell stock

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

CFO & Treasurer notifies of intention to sell stock

Recent updates

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Consensus EPS estimates increase by 27%

Lantheus Holdings: Powerful First Quarter

Price target increased by 8.3% to US$106

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

CFO & Treasurer notifies of intention to sell stock

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Chairman of the Board notifies of intention to sell stock

Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients

Investor sentiment improves as stock rises 15%

Lantheus Holdings: Undervalued With A Good Outlook

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Full year 2023 earnings: EPS exceeds analyst expectations

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)

Now 25% undervalued after recent price drop

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings

Investor sentiment deteriorates as stock falls 22%

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Price target decreased by 7.7% to US$108

Now 31% undervalued after recent price drop

CFO & Treasurer notifies of intention to sell stock

Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing

A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

CEO & Director notifies of intention to sell stock

Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?

New major risk - Earnings quality

New major risk - Revenue and earnings growth

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

CEO & Director notifies of intention to sell stock

Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New minor risk - Earnings quality

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?

Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging

Insufficient new directors

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Chief Administrative Officer notifies of intention to sell stock

Price target increased by 7.4% to US$120

Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Business Officer notifies of intention to sell stock

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

CEO & Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Investor sentiment improves as stock rises 17%

Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc.

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

Senior VP notifies of intention to sell stock

Investor sentiment deteriorated over the past week